Prevalence and diagnostic value of precordial murmurs for valvular regurgitation in obese patients treated with dexfenfluramine

American Journal of Cardiology

Volumn 86, Issue 5, 2000, Pages 535-539

  Roldan, Carlos A ^a   Gill, Edward A ^b   Shively, Bruce K ^c  

^a VA Medical Center   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXFENFLURAMINE;

ADULT; ARTICLE; COLOR ULTRASOUND FLOWMETRY; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE SEVERITY; DRUG INDUCED DISEASE; FEMALE; HEART MURMUR; HEART VALVE REGURGITATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PREVALENCE; PRIORITY JOURNAL; VALVULAR HEART DISEASE;

CASE-CONTROL STUDIES; DEXFENFLURAMINE; ECHOCARDIOGRAPHY, DOPPLER, COLOR; FEMALE; HEART AUSCULTATION; HEART MURMURS; HEART VALVE DISEASES; HUMANS; MALE; MIDDLE AGED; OBESITY; PREVALENCE; SEROTONIN AGONISTS;

EID: 0034284442     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(00)01008-0     Document Type: Article

References (17)

1. Connolly H.M., Crary J.L., McGoon M.D., Hensrud D.D., Edwards B.S., Edwards W.D., Schaff H.V. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 337:1997;581-588.
2. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services Interim Public Health Recommendations, November 1997; Morbidity and Mortality Weekly Report 1997:46:1061-1065.
3. Jick H., Vasilakis C., Weinrauch L.A., Meier C.R., Jick S.S., Derby L.E. A population based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med. 339:1998;719-724.
4. Khan M.A., Herzog C.A., St. Peter J.V., Hartley G.G., Madlon-Kay R., Dick C.D., Asinger R.W., Vessey J.T. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite suppressant drugs. N Engl J Med. 339:1998;713-718.
5. Weissman N.J., Tighe J.F., Gottdiener J.S., Gwynne J.T. An assessment of heart valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. N Engl J Med. 339:1998;725-732.
6. Burger A.J., Sherman H.B., Charlamb M.J., Kim J., Asinas L.A., Flickner S.R., Blackburn G.L. Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months. J Am Coll Cardiol. 34:1999;1153-1158.
7. Shively B.K., Roldan C.A., Gill E.A., Najarian T., Loar S. Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine. Circulation. 100:1999;2161-2167.
8. Kancherla M.K., Salti H.I., Mulderink T.A., Parker M., Bonow R.O., Mehlman D.J. Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine. Am J Cardiol. 84:1999;1335-1338.
9. Guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). Circulation. 98:1998;1949-1984.
10. Roldan C.A., Shively B.K., Crawford M.H. Value of the cardiovascular physical examination for detecting valvular heart disease in asymptomatic subjects. Am J Cardiol. 77:1996;1327-1331.
11. Rahko P.S. Prevalence of regurgitant murmurs in patients with valvular regurgitation detected by Doppler echocardiography. Ann Intern Med. 111:1989;466-472.
12. Lembo N.J., Dell'Italia L.J., Crawford M.H., O'Rourke R.A. Bedside diagnosis of systolic murmurs. N Engl J Med. 318:1988;1572-1578.
13. Aronow W.S., Kronzon I. Correlation of prevalence and severity of aortic regurgitation by pulsed Doppler echocardiography with murmur of aortic regurgitation in elderly patients in a long-term health care facility. Am J Cardiol. 63:1989;128-129.
14. Jaffe W.M., Roche A., Coverdale H.A., McAlester H.F., Ormiston J.A., Greene E.R. Clinical evaluation versus Doppler echocardiography in the quantitative assessment of valvular heart disease. Circulation. 78:1988;267-275.
15. Cannistra L.B., Cannistra A.J. Regression of multivalvular regurgitation after cessation of fenfluramine and phentermine treatment [letter]. N Engl J Med. 339:1998;771.
16. Hensrud D.D., Connolly H.M., Grogan M., Miller F.A., Bailey K.R., Jensen M.D. Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine. Mayo Clin Proc. 74:1999;1191-1197.
17. Weissman N.J., Tighe J.F., Gottdiener J.S., Gwynne J.T. Prevalence of valvular regurgitation associated with dexfenfluramine three to five months after discontinuation of treatment. J Am Coll Cardiol. 34:1999;2088-2095.